Skip to main content
. 2019 Mar 7;25(9):1142–1157. doi: 10.3748/wjg.v25.i9.1142

Table 9.

Individual studies included for induction of clinical remission in Crohn’s disease

Study Country Intervention Comparator Study design Follow-up n Induction of clinical remission
Thomsen et al[45] Denmark, France, United Kingdom, Norway, Italy, Spain, Portugal, Greece, South Africa, Austria, Australia, and Ireland Budesonide Mesalamine RCT 8 wk 182 69% (budesonide) 45% (mesalamine) (P = 0.001)1
Budesonide Mesalamine RCT 16 wk 182 62% (budesonide) 36% (mesalamine) (P < 0.001)1
Pavez et al[41] Chile IFX AZA RCT 26 wk 508 0.44 (event rate IFX); 0.3 (event rate AZA)2
1

Clinical remission defined as Crohn’s Disease Activity Index (CDAI) ≤ 150;

2

Clinical remission defined as CDAI less than 150 in patients who did not receive budesonide at a daily dose greater than 6 mg, or systemic corticosteroids for at least 3 wk. AZA: Azathioprine; IFX: Infliximab; n: Number of patients; RCT: Randomized clinical trial; CDAI: Crohn’s Disease Activity Index.